J. Vansteenkiste

发表

Erythropoiesis-stimulating agents in cancer patients: reflections on safety

I. Wauters, J. Vansteenkiste, 2011, Expert review of clinical pharmacology.

Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes

J. Berlin, J. Crawford, H. Ludwig, 2010, British Journal of Cancer.

Intravenous iron supplementation for the treatment of chemotherapy-induced anaemia – systematic review and meta-analysis of randomised controlled trials

L. Leibovici, L. Vidal, O. Shpilberg, 2013, Acta oncologica.

Darbepoetin alfa in the treatment of anemia in cancer patients undergoing chemotherapy

I. Wauters, J. Vansteenkiste, 2012, Expert review of anticancer therapy.

Darbepoetin alfa in the treatment of chemotherapy-induced anaemia

I. Wauters, J. Vansteenkiste, Isabelle Wauters, 2009 .

Pooled analysis of individual patient-level data from all randomized, double-blind, placebo-controlled trials of darbepoetin alfa in the treatment of patients with chemotherapy-induced anemia.

J. Crawford, H. Ludwig, K. Bridges, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Darbepoetin alfa for the treatment of chemotherapy-induced anemia: disease progression and survival analysis from four randomized, double-blind, placebo-controlled trials.

R. Amado, M. Hedenus, M. Austin, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effects of medroxyprogesterone acetate on appetite, weight, and quality of life in advanced-stage non-hormone-sensitive cancer: a placebo-controlled multicenter study.

N. Aaronson, M. Muller, E. Wouters, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Transfusion risk in cancer patients with chemotherapy-induced anemia when initiating darbepoetin alfa therapy at a baseline hemoglobin level of <9 g/dL versus 9 to <10 g/dL versus ≥10 g/dL: an exploratory analysis of a phase 3 trial

C. Bokemeyer, P. Gascón, J. Canon, 2012, Medical Oncology.

Final results of a randomized, double-blind, active-controlled trial of darbepoetin alfa administered once every 3 weeks (Q3W) for the treatment of anemia in patients receiving multicycle chemotherapy

J. Canon, G. Bodoky, J. Vansteenkiste, 2005 .

Darbepoetin alfa in lung cancer patients on chemotherapy: a retrospective comparison of outcomes in patients with mild versus moderate-to-severe anaemia at baseline

R. Pirker, D. Tomita, J. Vansteenkiste, 2004, Supportive Care in Cancer.

Flexible dosing with Darbepoetin alfa for the treatment of chemotherapy-induced anemia

I. Wauters, J. Vansteenkiste, K. Pat, 2006, Therapeutics and clinical risk management.

Melanoma-associated antigen-A3 vaccination in the treatment of non-small-cell lung cancer

I. Wauters, J. Vansteenkiste, V. Adam, 2014, Expert opinion on biological therapy.

Immunotherapy for non-small-cell lung cancer: the past 10 years.

N. De Brucker, I. Wauters, J. Vansteenkiste, 2015, Future oncology.

Phase II study of docetaxel alternating with cisplatin in chemotherapy-naïve patients with advanced non-small cell lung cancer

R. Stupp, U. Gatzemeier, M. Bargetzi, 2000, Anti-cancer drugs.

Darbepoetin alfa in the treatment of chemotherapy-induced anaemia.

I. Wauters, J. Vansteenkiste, 2009, Expert Opinion on Biological Therapy.

Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alpha administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia.

T. Pintér, J. Vansteenkiste, A. Vandebroek, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Osimertinib vs comparator EGFR-TKI as first-line treatment for EGFRm advanced NSCLC (FLAURA): Final overall survival analysis

Ying Cheng, Y. Ohe, B. Chewaskulyong, 2019, Annals of Oncology.

Observational Aranesp® Survey to Investigate the Q3W Schedule (OASIS): a prospective observational study of treatment of chemotherapy-induced anaemia with every 3 weeks darbepoetin alfa

M. Derde, M. Polus, I. Wauters, 2009, Supportive Care in Cancer.

Use of Erythropoiesis-stimulating Agents (ESAs) in Lung Cancer Patients: Study-level and Patient-level Meta-analyses of Safety Outcomes

J. Crawford, H. Ludwig, K. Bridges, 2010 .

Denosumab versus zoledronic acid in patients with bone metastases from solid tumors other than breast and prostate cancers or multiple myeloma: A number needed to treat (NNT) analysis.

S. Novello, M. Krzakowski, T. Ciuleanu, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Syndrome of inappropriate antidiuretic hormone associated with chemotherapy-induced tumour lysis in small-cell lung cancer: case report and literature review.

R. Paridaens, J. Vansteenkiste, J. Vansteenkiste, 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

Vandetanib plus pemetrexed versus pemetrexed as second-line therapy in patients with advanced non-small cell lung cancer (NSCLC): A randomized, double-blind phase III trial (ZEAL).

J. Vansteenkiste, F. Blackhall, J. Raats, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Sequential treatment with vindesine-ifosfamide-platinum (VIP) chemotherapy followed by platinum sensitized radiotherapy in stage IIIB non-small cell lung cancer: a phase II trial.

D. de Ruysscher, D. Ruysscher, J. Vansteenkiste, 1998, Lung Cancer.

Pooled analysis of individual patient-level data from all randomized, double-blind, placebo-controlled trials of darbepoetin alfa in the treatment of patients with chemotherapy-induced anemia.

J. Crawford, H. Ludwig, K. Bridges, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer

G. Scagliotti, Keunchil Park, F. de Marinis, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Diagnostic tests of hyperventilation syndrome.

J. Vansteenkiste, M. Demedts, M. Demedts, 1991, The European respiratory journal.

Melanoma-associated antigen-A3 vaccination in the treatment of non-small-cell lung cancer

I. Wauters, J. Vansteenkiste, V. Adam, 2014, Expert opinion on biological therapy.